癌症诊断后的胚系基因检测
该观察性研究纳入2013年至2019年加利福尼亚州和佐治亚州诊断为任何类型癌症的20岁及以上患者,链接4家实验室的胚系检测结果。在1 369 602例患者中,93 052例(6.8%)在诊断后2年内接受了胚系基因检测;不同癌种检测比例从肺癌0.3%到男性乳腺癌50%不等;亚裔、黑人和西班牙裔患者检测率低于非西班牙裔白人患者。
要点
- 在2013至2019年加州和佐治亚州癌症患者中,仅6.8%接受了胚系基因检测。
- 检测率因癌种而异:男性乳腺癌50%、卵巢癌38.6%、女性乳腺癌26%、肺癌0.3%。
- 亚裔、黑人和西班牙裔患者检测率低于非西班牙裔白人患者。
核心结论
- 在2013年至2019年加利福尼亚州和佐治亚州诊断为癌症的患者中,仅6.8%接受了胚系基因检测;亚裔、黑人和西班牙裔患者的检测率低于非西班牙裔白人患者。
研究设计与样本
- 观察性研究,纳入2013年1月1日至2019年3月31日期间诊断为任何类型癌症、年龄20岁及以上、报告至加利福尼亚州和佐治亚州全州监测、流行病学和最终结果(SEER)登记处的患者。
- 这些患者与4家为加利福尼亚州和佐治亚州进行大部分胚系检测的实验室的基因检测结果链接。
- 主要结局为癌症诊断后2年内的胚系基因检测;采用逻辑回归模型分析检测趋势。
主要发现
- 在2013年至2019年加利福尼亚州和佐治亚州诊断为癌症的1 369 602例患者中,93 052例(6.8%)截至2021年3月31日接受了胚系检测。
- 检测比例因癌症类型而异:男性乳腺癌50%、卵巢癌38.6%、女性乳腺癌26%、多发性癌7.5%、子宫内膜癌6.4%、胰腺癌5.6%、结直肠癌5.6%、前列腺癌1.1%、肺癌0.3%。
- 在逻辑回归模型中,与非西班牙裔白人男性乳腺癌、女性乳腺癌或卵巢癌患者接受检测的31%(95% CI,30%-31%)相比,其他种族和族裔患者接受检测的比例更低:亚裔患者22%(95% CI,21%-22%)、黑人患者25%(95% CI,24%-25%)、西班牙裔患者23%(95% CI,23%-23%)(χ2检验P < .001)。
- 在所有致病性结果中,67.5%至94.9%的变异位于实践指南推荐检测的基因中,68.3%至83.8%的变异位于与所诊断癌症类型相关的基因中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. OBJECTIVE: To describe the prevalence of germline genetic testing among patients diagnosed with cancer in California and Georgia between 2013 and 2019. DESIGN, SETTING, AND PARTICIPANTS: Observational study including patients aged 20 years or older who had been diagnosed with any type of cancer between January 1, 2013, and March 31, 2019, that was reported to statewide Surveillance, Epidemiology, and End Results registries in California and Georgia. These patients were linked to genetic testing results from 4 laboratories that performed most germline testing for California and Georgia. MAIN OUTCOMES AND MEASURES: The primary outcome was germline genetic testing within 2 years of a cancer diagnosis. Testing trends were analyzed with logistic regression modeling. The results of sequencing each gene, including variants associated with increased cancer risk (pathogenic results) and variants whose cancer risk association was unknown (uncertain results), were evaluated. The genes were categorized according to their primary cancer association, including breast or ovarian, gastrointestinal, and other, and whether practice guidelines recommended germline testing. RESULTS: Among 1 369 602 patients diagnosed with cancer between 2013 and 2019 in California and Georgia, 93 052 (6.8%) underwent germline testing through March 31, 2021. The proportion of patients tested varied by cancer type: male breast (50%), ovarian (38.6%), female breast (26%), multiple (7.5%), endometrial (6.4%), pancreatic (5.6%), colorectal (5.6%), prostate (1.1%), and lung (0.3%). In a logistic regression model, compared with the 31% (95% CI, 30%-31%) of non-Hispanic White patients with male breast cancer, female breast cancer, or ovarian cancer who underwent testing, patients of other races and ethnicities underwent testing less often: 22% (95% CI, 21%-22%) of Asian patients, 25% (95% CI, 24%-25%) of Black patients, and 23% (95% CI, 23%-23%) of Hispanic patients (P < .001 using the χ2 test). Of all pathogenic results, 67.5% to 94.9% of variants were identified in genes for which practice guidelines recommend testing and 68.3% to 83.8% of variants were identified in genes associated with the diagnosed cancer type. CONCLUSIONS AND RELEVANCE: Among patients diagnosed with cancer in California and Georgia between 2013 and 2019, only 6.8% underwent germline genetic testing. Compared with non-Hispanic White patients, rates of testing were lower among Asian, Black, and Hispanic patients.
引用
- Kurian AW, Abrahamse P, Furgal A, et al. Germline Genetic Testing After Cancer Diagnosis. JAMA. 2023. PMID: 37276540. doi:10.1001/jama.2023.9526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。